Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:APHBNYSEAMERICAN:ARMPNASDAQ:CGENOTCMKTS:NGENF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$1.94+2.6%$1.71$0.15▼$1.37$64.93MN/A842,200 shs2,881 shsARMPArmata Pharmaceuticals$2.17+11.9%$1.79$0.90▼$3.42$78.53M0.9470,250 shs43,768 shsCGENCompugen$1.78+2.3%$1.54$1.13▼$2.66$158.85M2.57368,550 shs94,601 shsNGENFNervGen Pharma$2.45+1.4%$2.83$1.46▼$5.10$151.58MN/A144,152 shs74,801 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHBAmpliphi Biosciences+2.65%-2.51%0.00%+22.78%-29.45%ARMPArmata Pharmaceuticals+11.86%+13.61%+12.44%+69.53%-40.71%CGENCompugen+2.30%+9.20%-2.73%+35.88%+6.59%NGENFNervGen Pharma+1.40%-9.55%+16.30%+18.55%+6.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AARMPArmata Pharmaceuticals2.3528 of 5 stars3.55.00.00.00.01.70.0CGENCompugen1.5691 of 5 stars3.53.00.00.01.10.00.0NGENFNervGen PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHBAmpliphi Biosciences 0.00N/AN/AN/AARMPArmata Pharmaceuticals 3.00Buy$9.00314.75% UpsideCGENCompugen 3.00Buy$4.00124.72% UpsideNGENFNervGen Pharma 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ARMP, NGENF, CGEN, and APHB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025NGENFNervGen PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/19/2025ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AARMPArmata Pharmaceuticals$5.17M15.19N/AN/A($1.33) per share-1.63CGENCompugen$27.86M5.70N/AN/A$0.62 per share2.87NGENFNervGen Pharma$150K1,010.56N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AARMPArmata Pharmaceuticals-$18.92M-$1.64N/AN/AN/AN/AN/A-25.06%8/12/2025 (Estimated)CGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)NGENFNervGen Pharma-$4.07MN/AN/A∞N/AN/A-73.14%-56.59%8/20/2025 (Estimated)Latest ARMP, NGENF, CGEN, and APHB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/ANGENFNervGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHBAmpliphi BiosciencesN/AN/AN/AARMPArmata PharmaceuticalsN/A0.120.12CGENCompugenN/A5.095.09NGENFNervGen Pharma0.0411.2111.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHBAmpliphi BiosciencesN/AARMPArmata Pharmaceuticals3.57%CGENCompugen12.22%NGENFNervGen PharmaN/AInsider OwnershipCompanyInsider OwnershipAPHBAmpliphi BiosciencesN/AARMPArmata Pharmaceuticals84.50%CGENCompugen9.50%NGENFNervGen PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableARMPArmata Pharmaceuticals7036.19 million5.61 millionNot OptionableCGENCompugen7089.24 million80.76 millionOptionableNGENFNervGen Pharma761.77 millionN/ANot OptionableARMP, NGENF, CGEN, and APHB HeadlinesRecent News About These CompaniesNervGen Strengthens Board Leadership to Accelerate Clinical and Corporate GrowthJuly 3 at 4:41 PM | newsfilecorp.comNNervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory MilestonesJuly 1 at 7:30 AM | newsfilecorp.comNNervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor RoleJune 18, 2025 | newsfilecorp.comNParadigm Capital doubles its price target on NervGen PharmaJune 17, 2025 | cantechletter.comCNervGen Pharma (NGENF) Gets a Buy from Raymond JamesJune 13, 2025 | theglobeandmail.comNervGen Pharma-Aktie stürzt nach Ergebnissen klinischer Studie abJune 2, 2025 | de.investing.comNervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord InjuryJune 2, 2025 | taiwannews.com.twTNervGen Pharma stock tumbles following clinical trial resultsJune 2, 2025 | in.investing.comNervGen, Sprott Climb to 52-Week Highs on NewsMay 21, 2025 | baystreet.caNervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific MeetingMay 21, 2025 | newsfilecorp.comNNervGen Pharma Grants Stock OptionsMay 16, 2025 | newsfilecorp.comNNervGen Pharma Reports Q1 2025 Financial Results and Provides Operational UpdatesMay 15, 2025 | newsfilecorp.comNNervGen Pharma Announces Results of Annual General Meeting of ShareholdersMay 7, 2025 | newsfilecorp.comNNervGen Pharma is a high-risk, high-reward stock, analyst saysApril 21, 2025 | cantechletter.comCNervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 21, 2025 | newsfilecorp.comNNervGen Pharma Updates on Equity Program, Raises Over $1.6 MillionApril 9, 2025 | tipranks.comNervGen Provides Quarterly "At-The-Market" Equity Program UpdateApril 9, 2025 | newsfilecorp.comNNervGen Provides Quarterly "At-The-Market" Equity Program UpdateApril 9, 2025 | newsfilecorp.comNNervGen Provides Quarterly "At-The-Market" Equity Program UpdateApril 9, 2025 | newsfilecorp.comNNervGen Pharma Reports 2024 Year-End Financial Results and Provides Business UpdatesApril 3, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARMP, NGENF, CGEN, and APHB Company DescriptionsAmpliphi Biosciences NYSEAMERICAN:APHB$1.94 +0.05 (+2.65%) As of 07/2/2025AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Armata Pharmaceuticals NYSEAMERICAN:ARMP$2.17 +0.23 (+11.86%) As of 07/3/2025 05:00 PM EasternArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Compugen NASDAQ:CGEN$1.78 +0.04 (+2.30%) Closing price 07/3/2025 02:20 PM EasternExtended Trading$1.79 +0.01 (+0.51%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.NervGen Pharma OTCMKTS:NGENF$2.45 +0.03 (+1.40%) As of 07/3/2025 12:56 PM EasternNervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
